tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Cory Kasimov, 50 are a HOLD (34.01%), 95 are a BUY (64.63%), 2 are a SELL (1.36%).
Analyst Cory Kasimov, currently employed at EVERCORE, carries an average stock price target met ratio of 60.85% that have a potential upside of 31.63% achieved within 309 days. Previously, Cory Kasimov worked at JPMORGAN.
Cory Kasimov’s has documented 276 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 02-Sep-2025.
Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$33
$10.98 (49.86%)
$34
1 months 2 days ago
(28-Sep-2025)
8/13 (61.54%)
$11.68 (54.78%)
113
Buy
$28
$5.98 (27.16%)
$30
1 months 7 days ago
(23-Sep-2025)
0/10 (0%)
$6.74 (31.70%)
Buy
$39
$16.98 (77.11%)
$35
1 months 20 days ago
(10-Sep-2025)
7/12 (58.33%)
$14.8 (61.16%)
671
Buy
$39
$16.98 (77.11%)
$32
1 months 22 days ago
(08-Sep-2025)
1/5 (20%)
$14.16 (57.00%)
349
Hold
$24
$1.98 (8.99%)
$23
2 months 24 days ago
(06-Aug-2025)
10/13 (76.92%)
$-0.4 (-1.64%)
157
Which stock is Cory Kasimov is most bullish on?
Which stock is Cory Kasimov is most reserved on?
What Year was the first public recommendation made by Cory Kasimov?
